Close Menu
June 11, 2019
Sponsored by

The Promise of Liquid Biopsy in Lung Cancer Monitoring


Head of the Cancer Genome Research Division; German Cancer Research Center

This webinar provides an overview on the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Lung adenocarcinoma is the most prevalent subtype of lung cancer and characterized by considerable morphological and mutational heterogeneity, which is the primary source of therapy resistance and tumor progression. For many targeted treatments, the underlying molecular alterations leading to therapy resistance are well established. However, frequent tissue sampling to verify such alterations and adapt treatment strategies is not possible. Liquid biopsy approaches are potentially appropriate to overcome these obstacles: Circulating tumor DNA might be superior to tissue biopsies in representing tumor heterogeneity. In addition, frequent blood draws are feasible to monitor molecular alterations even in research subjects who suffer from substantial comorbidities.   

In this webinar, Dr. Holger Sültmann of the German Cancer Research Center discusses liquid biopsy approaches to monitor lung cancer progression using tumor markers in the blood. The focus will be on nucleic acid mutation detection and quantification in clinical samples and their relevance for diagnostics.

The webinar also addresses strengths and limitations of PCR- and NGS-based analysis technologies.

Sponsored by

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

Sponsored by

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.